QUOTE AND NEWS
Benzinga  Jul 1  Comment 
In a report published Wednesday, HC Wainwright analyst Swayampakula Ramakanth initiated coverage of Novogen Limited (ADR) (NASDAQ: NVGN) with a Buy rating and $8.50 price target. The company has three drug candidates that target an addressable...
Benzinga  Jun 24  Comment 
Novogen Limited (NASDAQ: NVGN), announced today that its candidate cytotoxic chemotherapy drug, Anisina, has proved an effective anti-cancer agent in animals, the result of which it now has been fast-tracked by the Company to come into the...
Benzinga  Jun 12  Comment 
Novogen Limited (NASDAQ: NVGN) today announced today that Novogen Group CEO, Graham Kelly, will be presenting at the Bio International Convention 2015 (BIO) being held at the Pennsylvania Convention Centre, 1101 Arch St, Philadelphia, PA...
The Australian  Jun 5  Comment 
Novogen has made a breakthrough in the development of its anti-cancer drug which has potential use in treating brain tumours.
Benzinga  Jun 4  Comment 
Novogen Limited (NASDAQ: NVGN) confirms that a lipid formulation of TRXE-009 dosed intravenously to animals was able to deliver therapeutic concentrations of TRXE-009 to brain tissue. This confirms that the drug is able to cross the blood brain...
Benzinga  Jun 2  Comment 
Novogen Limited (NASDAQ: NVGN), announced today the non-renounceable pro-rata rights issue entitlement announced on 21 April 2015 (Rights Issue) was completed successfully. The Rights Issue offered up to 58,971,207 new shares at an issue price...
Benzinga  May 28  Comment 
Novogen Limited (NASDAQ: NVGN), announced today the lodgement with the US Patent Office of a key patent covering a novel family of compounds within the Company's anti-tropomyosin (ATM) drug technology platform. These structurally novel compounds...
Benzinga  May 18  Comment 
Novogen Limited (NASDAQ: NVGN), announced today that company CEO, Dr Graham Kelly, will be a presenting company at Asia Biotech Invest 2015 May 20-21. The Novogen presentation is at 10.00 am May 20 at the Sheraton Hotel and Towers, Hong...
Benzinga  May 14  Comment 
US-Australian drug discovery company, Novogen (NASDAQ: NVGN), today announced that it has confirmed that drug candidate, Anisina, is an effective monotherapy against human melanoma in an animal model. The Company announced recently that Anisina...
Benzinga  May 8  Comment 
Novogen Limited (ADR) (NASDAQ: NVGN) gained 16.82 percent to $7.50 in pre-market trading. According to a Thursday's press release, Australian Studies confirmed that TRXE-009 kills resistant paediatric brain cancer cells. XOMA Corp (NASDAQ:...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki